Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Loss of serum IGF-I input to the brain as an early biomarker of disease onset in Alzheimer mice.

Trueba-Sáiz A, Cavada C, Fernandez AM, Leon T, González DA, Fortea Ormaechea J, Lleó A, Del Ser T, Nuñez A, Torres-Aleman I.

Transl Psychiatry. 2013 Dec 3;3:e330. doi: 10.1038/tp.2013.102.

2.
5.

Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease?

Carro E, Trejo JL, Spuch C, Bohl D, Heard JM, Torres-Aleman I.

Neurobiol Aging. 2006 Nov;27(11):1618-31. Epub 2005 Nov 7.

PMID:
16274856
6.

Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine.

Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM.

J Alzheimers Dis. 2005 Dec;8(3):247-68.

PMID:
16340083
7.

Targeting insulin-like growth factor-1 to treat Alzheimer's disease.

Torres-Aleman I.

Expert Opin Ther Targets. 2007 Dec;11(12):1535-42. Review.

PMID:
18020976
8.

Increased circulating insulin-like growth factor-1 in late-onset Alzheimer's disease.

Vardy ER, Rice PJ, Bowie PC, Holmes JD, Grant PJ, Hooper NM.

J Alzheimers Dis. 2007 Dec;12(4):285-90.

PMID:
18198415
9.

Relationship between serum insulin-like growth factor-1 levels and Alzheimer's disease and vascular dementia.

Watanabe T, Miyazaki A, Katagiri T, Yamamoto H, Idei T, Iguchi T.

J Am Geriatr Soc. 2005 Oct;53(10):1748-53.

PMID:
16181175
10.

Early brain amyloidosis in APP/PS1 mice with serum insulin-like growth factor-I deficiency.

Poirier R, Fernandez AM, Torres-Aleman I, Metzger F.

Neurosci Lett. 2012 Feb 16;509(2):101-4. doi: 10.1016/j.neulet.2011.12.048. Epub 2011 Dec 31.

PMID:
22230888
11.

Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type.

Tham A, Nordberg A, Grissom FE, Carlsson-Skwirut C, Viitanen M, Sara VR.

J Neural Transm Park Dis Dement Sect. 1993;5(3):165-76.

PMID:
7690227
12.

Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease.

Freude S, Hettich MM, Schumann C, Stöhr O, Koch L, Köhler C, Udelhoven M, Leeser U, Müller M, Kubota N, Kadowaki T, Krone W, Schröder H, Brüning JC, Schubert M.

FASEB J. 2009 Oct;23(10):3315-24. doi: 10.1096/fj.09-132043. Epub 2009 Jun 1.

PMID:
19487308
13.

Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models.

Lanz TA, Salatto CT, Semproni AR, Marconi M, Brown TM, Richter KE, Schmidt K, Nelson FR, Schachter JB.

Biochem Pharmacol. 2008 Mar 1;75(5):1093-103. Epub 2007 Nov 12.

PMID:
18076866
14.

Possible usefulness of growth hormone/insulin-like growth factor-I axis in Alzheimer's disease treatment.

Sáez JM.

Endocr Metab Immune Disord Drug Targets. 2012 Sep;12(3):274-86. Review.

PMID:
22524398
15.

Insulin-like growth factor-I and its receptor in the frontal cortex, hippocampus, and cerebellum of normal human and alzheimer disease brains.

Jafferali S, Dumont Y, Sotty F, Robitaille Y, Quirion R, Kar S.

Synapse. 2000 Dec 15;38(4):450-9.

PMID:
11044892
16.

Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor I.

Carro E, Spuch C, Trejo JL, Antequera D, Torres-Aleman I.

J Neurosci. 2005 Nov 23;25(47):10884-93.

17.

Cellular distribution of insulin-like growth factor-II/mannose-6-phosphate receptor in normal human brain and its alteration in Alzheimer's disease pathology.

Kar S, Poirier J, Guevara J, Dea D, Hawkes C, Robitaille Y, Quirion R.

Neurobiol Aging. 2006 Feb;27(2):199-210. Epub 2005 Apr 9.

PMID:
16399207
18.

Reduced brain insulin-like growth factor I function during aging.

Muller AP, Fernandez AM, Haas C, Zimmer E, Portela LV, Torres-Aleman I.

Mol Cell Neurosci. 2012 Jan;49(1):9-12. doi: 10.1016/j.mcn.2011.07.008. Epub 2011 Jul 23.

PMID:
21807098
19.

Oral administration of a GSK3 inhibitor increases brain insulin-like growth factor I levels.

Bolós M, Fernandez S, Torres-Aleman I.

J Biol Chem. 2010 Jun 4;285(23):17693-700. doi: 10.1074/jbc.M109.096594. Epub 2010 Mar 29.

20.

IGF-I gene variability is associated with an increased risk for AD.

Vargas T, Martinez-Garcia A, Antequera D, Vilella E, Clarimon J, Mateo I, Sanchez-Juan P, Rodriguez-Rodriguez E, Frank A, Rosich-Estrago M, Lleo A, Molina-Porcel L, Blesa R, Gomez-Isla T, Combarros O, Bermejo-Pareja F, Valdivieso F, Bullido MJ, Carro E.

Neurobiol Aging. 2011 Mar;32(3):556.e3-11. doi: 10.1016/j.neurobiolaging.2010.10.017. Epub 2010 Dec 22.

PMID:
21176999

Supplemental Content

Support Center